Zynlonta FDA Approval History
Last updated by Judith Stewart, BPharm on May 2, 2021.
FDA Approved: Yes (First approved April 23, 2021)
Brand name: Zynlonta
Generic name: loncastuximab tesirine-lpyl
Dosage form: Injection
Company: ADC Therapeutics SA
Treatment for: Diffuse Large B-cell Lymphoma
Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
- Zynlonta is administered via intravenous infusion over 30 minutes on Day 1 of each cycle (every 3 weeks). Oral or IV dexamethasone is recommended as a premedication twice daily for 3 days starting the day before treatment to minimize the chance of side effects.
- Zynlonta may cause serious side effects including fluid retention, low blood cell counts, infections, and skin reactions. Common side effects include thrombocytopenia, increased gamma-glutamyltransferase, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edema, nausea, and musculoskeletal pain.
Development timeline for Zynlonta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.